The global therapeutic drug monitoring market is valued at USD 2.2 Billion in 2021 and projected to reach 3.5 Billion by 2028, witnessing at a CAGR rate of 4.9% during the forecast period 2022-2028. Therapeutic Drug Monitoring is a measurement of drug concentrations or drug metabolites in plasma. It is usually carried out for narrow therapeutic index drugs. Therapeutic drug monitoring is the clinical assessment of drug’s pharmacokinetic properties. TDM helps in reduce drug toxicity, enhance drug efficacy and diagnostic purpose. Various drug molecules usually monitored at clinical practice. For example: drugs like digoxin, cyclosporin, phenytoin, carbamazepine and valproic acid, among others. Tricyclic antidepressants (TCAs) such as Amitriptyline, Nortriptyline, Imipramine, and Clomipramine are frequently preferred for TDM due to their slow onset of action the difficulty of assessing dose-effect, and the marked interindividual variability of steady-state plasma concentration. In general, LC-MS/MS is highly preferred for TDM of tricyclic antidepressants due to structural similarity of the drugs. Immunosuppressant drugs are mostly used in organ transplantation cases. Patients using ISD’s commonly undergo TDM owing to their narrow therapeutic index, variability in blood concentrations between individuals and severe adverse effects. In terms of technology, LC-MS/MS accounts for more than USD 730 Million in 2018 followed by immunoassay, Others and GC/GC-MS. In terms of value, LC-MS/MS dominate the global TDM market followed by the immunoassays segment owing to its sensitivity, specificity towards the identification analytes and simultaneous analysis of the multiple drugs and analytes in the blood. However, in terms of volume Immunoassays dominate the market and they are cost effective when compared with other reagents. The report gives historical, current, and future market sizes (US$ Bn) based on Technology, Drug class, and Geography. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.
In March 2022, Beckman Coulter, a global clinical diagnostics leader, announced that the company will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as Schizophrenia and Bipolar Disorder. These new assays are developed using an innovative nanoparticle technology and empower health care professionals with data to monitor psychiatric drugs prescribed in treatment of psychosis: Clozapine, Risperidone/Paliperidone, Olanzapine, Quetiapine, Aripiprazole.
In August 2019, Ortho Clinical Diagnostics, a global leader in in-vitro diagnostics, in collaboration with Thermo Fisher Scientific, has expanded Drugs of Abuse and Therapeutic Drug Assay menus on MicroTip-capable VITROS® Systems to enable testing for fentanyl, a commonly abused opioid, and tricyclic antidepressant (TCA), which has a narrow safe therapeutic range.